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Sir, Sleepiness and disrupted sleep substantially impair
quality of life in people with Parkinson’s disease (PD)
(Arnulf et al., 2000). The hypocretin/orexin neuropeptides
stabilize wakefulness and sleep, and in two recent studies,
Fronczek et al. (2007) and Thannickal et al. (2007) showed
that patients with late-stage PD have a 38–45% loss of the
hypothalamic hypocretin-producing neurons. These studies
provide novel and important insights into the neuropathol-
ogy of PD, but several questions remain about whether this
partial loss of hypocretin neurons actually causes the sleep–
wake disturbances of PD.
First, are the sleep-related symptoms of PD consistent
with a loss of hypocretin neurons? Narcolepsy is caused by
a 90–95% loss of the hypocretin neurons and is
characterized by excessive daytime sleepiness and cataplexy
(sudden loss of muscle tone with strong emotions), with
fragmented sleep, sleep paralysis (immobility either at sleep
onset or upon awakening), hypnagogic hallucinations and
sleep-onset REM sleep (SOREM) during daytime naps
(Bassetti and Aldrich, 1996; Peyron et al., 2000). Certainly,
PD patients often have fragmented sleep, daytime sleepi-
ness, SOREM, and hallucinations (Arnulf et al., 2000). Our
own clinical experience, however, is not in agreement with
the statements by Thannickal et al. that the daytime sleep
attacks in PD resemble sleep attacks in narcolepsy, nor do
we agree that sleep–wake disturbances are often more
disturbing for PD patients than their motor symptoms.
Furthermore, narcoleptics may have hypnagogic hallucina-
tions at the transitions between wakefulness and sleep, but
PD patients often have delusions and illusions rather than
dream-like hallucinations (Aarsland et al., 1999). Last,
cataplexy has not been reported to occur in PD. Therefore,
while there are some similarities, the sleepiness and other
symptoms of PD differ in many ways from those seen in
narcolepsy.
Second, do patients with PD have a physiologically
significant loss of hypocretin signalling? In narcolepsy with
cataplexy, the almost complete loss of hypocretin neurons is
accompanied by severe reductions in lumbar CSF hypocre-
tin levels (Peyron et al., 2000; Thannickal et al., 2000;
Nishino et al., 2000). However, most studies have found
normal hypocretin levels in PD (Ripley et al., 2001;
Overeem et al., 2002; Yasui et al., 2006). In fact, we
found normal CSF concentrations of hypocretin even in
PD patients with objectively confirmed severe excessive
daytime sleepiness, hallucinations and SOREMs (Baumann
et al., 2005a).
One group reported very low hypocretin levels in
ventricular CSF of late-stage PD patients (Drouot et al.,
2003), raising the question of whether ventricular or
lumbar CSF more accurately reflects the integrity of the
hypocretin system. Fronczek et al. found that hypocretin
levels in ventricular CSF of PD patients are slightly reduced
compared to controls and correlate with the loss of
hypocretin neurons, but in the absence of normative data,
it is unclear whether these levels are physiologically low.
In two patients with simultaneous sampling of lumbar and
ventricular CSF, we found no significant differences in
hypocretin levels (Baumann et al., 2005b). Overall, it
appears that in patients with PD, hypocretin signalling as
measured in CSF appears normal.
Third, does PD selectively injure the hypocretin neurons?
Thannickal et al. found that hypothalami of PD patients also
have fewer neurons producing melanin concentrating hor-
mone. This supports the assumption that PD kills many types
of hypothalamic neurons, and loss of non-hypocretin neurons
may contribute to the sleep–wake disturbances of PD.
Overall, we suspect that the moderate loss of hypocretin
neurons in PD is accompanied by compensation in the
remaining cells to achieve relatively normal hypocretin
signalling. Furthermore, hypocretin cell loss may be a non-
specific finding of late-stage PD, in which injury to many
neuronal systems produces sleep–wake disturbances differ-
ent from those seen in narcolepsy.
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